Document is current
Any future updates will be listed below
-
Authors
Dong, Zhaojie
Du, Xin
Lu, Shangxin
Jiang, Chao
Xia, Shijun
He, Liu
Su, Xin
Jia, Zhaoxu
Long, Deyong
Sang, Caihua
Tang, Ribo
Liu, Nian
Bai, Rong
Yu, Ronghui
Dong, Jianzeng
Ma, Changsheng https://orcid.org/0000-0002-5387-5957
-
Clinical Trials BETA
Clinical trials referenced in this document:
chictr-och-13003729 at Chinese Clinical Trial RegistryDocuments that mention this clinical trial
-
Funding
Funding for this research was provided by:
National Key Research and Development Program of China (2016YFC0900901)
National Key Research and Development Program of China (2016YFC1301002, 2018YFC1312501, 2020YFC2004803)
National Key Research and Development Program of China (2017YFC0908803)
- License Information
-
More Information
Article History
Received: 10 November 2020
Accepted: 9 March 2021
First Online: 19 March 2021
Declarations
:
: The study was approved by the Ethics Committee on Human Research of Beijing Anzhen Hospital, the Capital Medical University. All participants provided written informed consent. Name of the ethics committee: Ethics Committee of Beijing Anzhen Hospital. Reference number: D11110700300000.
: Not applicable.
: Chang-sheng Ma has received honoraria from Bristol-Myers Squibb, Pfizer, Johnson & Johnson, Boehringer-Ingelheim, and Bayer for giving lectures. Jian-zeng Dong has received honoraria from Johnson & Johnson for giving lectures. The rest of the authors have declared no conflict of interest.
